This morning we watched Natera rise 6.4% to a price of $114.57 per share. The Large-Cap Medical Specialities company is now trading -8.63% below its average target price of $125.39. Analysts have set target prices ranging from $37.0 to $160.0 per share for Natera, and have given the stock an average rating of buy.
Natera has an average level of shares sold short, at 5.3% of its total share float. The stock's short ratio (also called days to cover) is 5.59. The company's insiders own 3.6% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 98.9% of Natera's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Natera
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 9% | 11,044,743 | $1,265,396,202 |
| 2024-03-31 | JP Morgan Chase & Company | 6% | 7,357,916 | $842,996,433 |
| 2024-03-31 | Fred Alger Management, LLC | 5% | 6,546,927 | $750,081,424 |
| 2024-03-31 | Blackrock Inc. | 5% | 6,485,931 | $743,093,112 |
| 2024-03-31 | Farallon Capital Management LLC | 3% | 3,927,683 | $449,994,640 |
| 2024-03-31 | Ameriprise Financial, Inc. | 3% | 3,441,930 | $394,341,919 |
| 2024-03-31 | Invesco Ltd. | 3% | 3,210,099 | $367,781,041 |
| 2024-03-31 | State Street Corporation | 2% | 2,722,993 | $311,973,307 |
| 2024-03-31 | Millennium Management Llc | 2% | 2,639,254 | $302,379,329 |
| 2024-03-31 | Alliancebernstein L.P. | 2% | 2,619,459 | $300,111,416 |
